GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Valuation Rank

Helix BioPharma (TSX:HBP) Valuation Rank


View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Helix BioPharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Valuation Rank
Comparable Companies
TSXV:GSD TSXV:NRX TSX:SVA NEOE:BMND TSXV:SHRX TSXV:TTI XCNQ:DTC TSX:MBX XCNQ:DOSE TSXV:COV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
HBP0:Germany
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Website
https://www.helixbiopharma.com
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.